Ranbaxy’s Paonta Site Clears Joint Inspection By Five Regulators
This article was originally published in PharmAsia News
Executive Summary
In contrast to FDA 483 observations, regulatory agencies from four countries and the World Health Organization have cleared Ranbaxy’s controversial Paonta Sahib unit in India.